Ibuprofen intravenous - Cumberland Pharmaceuticals

Drug Profile

Ibuprofen intravenous - Cumberland Pharmaceuticals

Alternative Names: Amelior; Caldolor; Ibuprofen injection

Latest Information Update: 15 Apr 2016

Price : $50

At a glance

  • Originator Cumberland Pharmaceuticals
  • Developer Al-Nabil; Alveda Pharma; bioCSL; Cumberland Pharmaceuticals; DB Pharm Korea; GerminMED; Grifols; Piramal Critical Care; PT SOHO Industri Pharmasi; PT. ETHICA Industri Farmasi; Sandor Medicaids
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Fever; Pain

Most Recent Events

  • 24 Mar 2016 Launched for Pain (In adolescents, In children, In infants) in USA (IV)
  • 24 Mar 2016 Launched for Fever (In adolescents, In children, In infants) in USA (IV)
  • 14 Mar 2016 Cumberland Pharmaceuticals and Laboratorios Grifols enter into a licensing agreement to develop Caldolor® in Spain, Portugal, and the majority of South America (Cumberland Pharmaceuticals, Form 10-K, March 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top